Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Biotherapy and Radiopharmaceuticals is Scopus-indexed (Q1, CiteScore 5.9), WoS SCIE. Published by SAGE Publications Ltd.
Checked against the index lists dated .
ISSN 1084-9785Verify ISSN ↗1557-8852Verify ISSN ↗
Publisher: SAGE Publications Ltd
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Radiology, Nuclear Medicine and Imaging | 65 / 361 | 82nd | Q1 |
| Oncology | 117 / 428 | 72nd | Q2 |
| Pharmacology | 109 / 328 | 66th | Q2 |
| Cancer Research | 100 / 233 | 57th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1996–present, best quartile Q1, CiteScore 5.9.
Cancer Biotherapy and Radiopharmaceuticals is Q1 in Radiology, Nuclear Medicine and Imaging (rank 65 of 361), Q2 in Oncology (rank 117 of 428) and Q2 in Pharmacology (rank 109 of 328), by CiteScore 2025. It is ranked in 4 subject areas in all.
Cancer Biotherapy and Radiopharmaceuticals is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.9, which places it in quartile Q1 at the 82nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.498, quartile Q2, with an H-index of 74.
Cancer Biotherapy and Radiopharmaceuticals is published by SAGE Publications Ltd. Its print ISSN is 1084-9785 and its online ISSN is 1557-8852.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer Biotherapy and Radiopharmaceuticals has an h-index of 77 and a 2-year mean of 1.04 citations per paper (OpenAlex). Its Scopus CiteScore is 5.9, quartile Q1. On 2-year citations it ranks #214 of 346 Scopus journals in Radiology, Nuclear Medicine and Imaging.
Cancer Biotherapy and Radiopharmaceuticals published 88 papers in 2025; its busiest recent year was 2020 with 219. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from China (66.1%), India (15.5%) and Türkiye (4%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 49 retracted papers are recorded (19.4 per 1,000 papers). The Problematic Paper Screener flags 9 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.